Adams Respiratory kept at sector perform by RBC

RBC Capital Markets analyst Ken Trbovich maintained Adams Respiratory Therapeutics Inc. at sector perform, above average risk, and a 12-month price target of $50. According to the analyst, a generic version of Mucinex and Humibid would reach the market no later than April 2009. Since Mutual intends to file future abbreviated New Drug Applications for guaifenesin combinations, the entire Adams Mucinex product family and Humibid prescription brands should be considered at risk of generic competition. Shares of the Chester, N.J.-based specialty pharmaceutical company were down $1.00, or 2.40%, at $40.75, on volume of 792,053 shares versus the three-month running average of 348,455 shares. (Nasdaq: ARXT)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.